The Luxembourg-domiciled Sicav will invest in “innovative biotechnology and biotechnology-related companies that seek to address high unmet medical needs around the world,” the group said. “The fund will target long-term growth within this fast growing and innovative sector.”
The fund will be co-managed by Andy Acker and Dan Lyons, who have more than 40 years of combined experience investing in biotechnology.
Ignacio de la Maza, Head of Continental Europe, Wholesale & Latin America said: ‘We are launching the fund to meet the needs of those clients searching for additional opportunities to invest in biotechnology. The fund will be managed by a team of experts with extensive scientific backgrounds and supported by the larger Janus Henderson healthcare investment team.’
Andy Acker noted: “The pace of progress in the biotechnology industry is accelerating, leading to more rapid medical breakthroughs. So far in 2018, the FDA has approved 55 new therapies – an all-time record.”
Dan Lyons added: “Our process focuses on the scientific and business drivers that are critical to mitigating the risks and uncovering the opportunities presented by this dynamic sector.”